Skip to main content
BioInvent International logo

BioInvent International — Investor Relations & Filings

Ticker · BINV ISIN · SE0015244520 LEI · 549300E7QRHEF2IJUY10 ST Manufacturing
Open in API
Filings indexed 679 across all filing types
Latest filing 2021-01-18 Board/Management Inform…
Country SE Sweden
Listing ST BINV

About BioInvent International

https://www.bioinvent.com/en

BioInvent International is a clinical-stage company that discovers and develops novel, first-in-class immuno-modulatory antibodies for cancer therapy. Leveraging extensive expertise in immunology, cancer biology, and antibody biology, the company generates innovative immuno-oncology drug candidates for its clinical pipeline. BioInvent's operations include an in-house manufacturing facility to produce antibodies for its preclinical studies and clinical trials, with the goal of developing treatments that can transform the lives of cancer patients.

Recent filings

Filing Released Lang Actions
An van Es Johansson resigns as board director in BioInvent International AB
Board/Management Information Classification · 99% confidence The document is a short press release dated January 18, 2021, announcing that 'An van Es Johansson will resign as a director of the board effective as of 15 February 2021.' This explicitly details a change in the company's board of directors/senior management. This directly matches the definition for Board/Management Information (MANG). The document length is short, but it is the primary announcement itself, not an announcement *about* another report, so RPA/RNS is not the primary fit.
2021-01-18 English
An van Es Johansson avgår som styrelseledamot i BioInvent International AB
Board/Management Information Classification · 100% confidence The document text is a short announcement in Swedish stating that a board member, An van Es Johansson, will resign from her position on the board of directors of BioInvent International AB, effective February 15, 2021. This directly concerns a change in the company's board of directors or senior management. According to the definitions, this aligns perfectly with the 'Board/Management Information' category. Filing Type Code: MANG. Confidence Score: 1.0.
2021-01-18 Swedish
BioInvent reviderar avtal avseende anti-Fc?RllB-antikroppen BI-1206, före data från fas I/II-studier
Regulatory Filings Classification · 98% confidence The document is titled 'PRESSMEDDELANDE' (Press Release) and is dated January 11, 2021. It announces a revision to an agreement regarding the clinical development of an antibody (BI-1206) with Cancer Research UK (CRUK). The text details financial implications (one-time payment, reduced royalties) and strategic flexibility gained. The concluding paragraph explicitly states: 'Denna information är sådan information som BioInvent International AB är skyldigt att offentliggöra enligt EU:s marknadsmissbruksförordning. Informationen lämnades, genom ovanstående kontaktpersons försorg, för offentliggörande den 11 januari 2021 kl. 8.15 CET.' This structure—a formal announcement of material, non-public information required under market abuse regulation—is characteristic of a general regulatory announcement, often categorized as RNS (Regulatory News Service) in European contexts, or a general press release that doesn't fit a more specific financial report type (like 10-K, ER, or IR). Since it is not a full report (like 10-K or IR) but a specific corporate action announcement, and it doesn't fit DIRS, DIV, CAP, or MANG, the most appropriate general regulatory filing category is RNS.
2021-01-11 Swedish
BioInvent streamlines agreement on anti-Fc?RllB antibody, BI-1206, ahead of Phase I/II data
Regulatory Filings Classification · 100% confidence The document is explicitly labeled as a "PRESS RELEASE" dated January 11, 2021. It announces a restructuring of a clinical development agreement concerning the antibody BI-1206 and mentions upcoming data. This type of announcement, which details corporate actions, agreements, or material operational updates outside of standard periodic financial reports (like 10-K or IR), typically falls under general regulatory announcements or press releases. Since it is not a full financial report (10-K, IR), an earnings release (ER), or a specific transaction report (like DIRS or POS), and it is a formal announcement, it best fits the 'Regulatory Filings' (RNS) category as a general regulatory disclosure, or potentially an 'Earnings Release' (ER) if it were summarizing results, but here it focuses on an agreement restructuring. Given the content is a corporate update/press release, RNS is the most appropriate general regulatory filing category for non-standard disclosures.
2021-01-11 English
Ändring av antalet aktier och röster i BioInvent International AB
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a press release dated December 30, 2020, announcing a change in the total number of outstanding shares and votes following a directed share issue and a subsequent 1:25 reverse stock split. This action directly impacts the company's capital structure and share count. Based on the definitions, the most appropriate category is 'Capital/Financing Update' (CAP), as it details a change in the number of shares outstanding resulting from financing activities (the directed emission). It is not a general regulatory filing (RNS) because it fits a more specific category, nor is it a formal share issue announcement (SHA) which usually relates to the initial decision or offering, although it is closely related. Since it details the final result of a capital change event, CAP is the best fit over SHA or RNS.
2020-12-30 Swedish
BioInvent erhåller betalning på 3 miljoner USD avseende val av antikroppar inom ramen för samarbetet med Pfizer Inc.
Capital/Financing Update Classification · 95% confidence The document is explicitly titled "PRESSMEDDELANDE" (Press Release) and is dated December 23, 2020. It announces a specific corporate event: Pfizer exercising an option and making a milestone payment of $3 million to BioInvent regarding an antibody collaboration. This type of announcement, detailing a specific corporate transaction, partnership milestone, or material event outside of routine financial reporting (like earnings or annual reports), is best classified as a general Regulatory Filing or announcement. Since it is not a formal financial report (10-K, IR, ER), a management discussion (MDA), or a specific insider trade (DIRS), the most appropriate category is the general regulatory announcement fallback, RNS, as it is a public disclosure required under market regulations (mentioned at the end: "EU:s marknadsmissbruksförordning"). It is too specific for a general 'LTR' (Legal) or 'CAP' (Financing).
2020-12-23 Swedish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.